Lantern Pharma, a NASDAQ-listed company specializing in AI-driven cancer drug discovery and development, has announced a milestone with its artificial intelligence platform …
Lantern Pharma’s AI-driven drug discovery platform RADR® enables value creation across multiple dimensions of the oncology drug development process: from …
Exscientia plc, a UK-based AI-driven precision medicine company, has initiated a clinical study, EXCYTE-2, focusing on acute myeloid leukaemia (AML) patients. …
We use cookies to personalise content and to analyse our traffic.
You consent to our cookies if you continue to use our website. Read more details in our
cookies policy.